“Because Lewis only complained of regulatory, rather than fraudulent, violations in his internal communications with AbbVie, the company had no reason to think Lewis’s concerns revolved around the False Claims Act. More simply, AbbVie could not have retaliated against Lewis as a fraud whistleblower because he never blew the whistle on fraud, U.S. Court of Appeals for the Seventh Circuit Judge Joshua P. Kolar said.
